Company developing gene therapy system, using the E. coli enzyme, purine nucleoside phosphorylase, to induce suicide in tumor cells. Includes technology background, research, patents, publications, key staff, and contacts in Birmingham, Alabama.
Conducts research and development for marketing cell-based vaccines and human monoclonal antibody against CD55 in tumour cells. Includes explanation of products in pipeline, and clinical studies in phase II of prostate cancer vaccine at Bournemouth, and their contacts in London, UK.
Oncology studies in small molecule histone deacetylase and topoisomerase II inhibitors, with clinical trials in solid tumours, CNS and extravasation. Technology and profile of company with facilities in Copenhagen and Abingdon, England.
Focus on CNS conformational diseases and oncology, using a combination of antibodies produced to non-covalent complexes of peptide sequences, presented as liposomes. Technical and corporate overviews of company in Lausanne, Switzerland.
Researches and develops novel therapeutic and diagnostic products to treat chronic debilitating diseases such as cancer, central nervous system disorders and autoimmune diseases. Based in Massachusetts. (Nasdaq: BLSI).
Development and commercialization of vaccines, and treatments, such as telomere homologs and angiogenesis inhibition. Includes product pipeline, clinical trials, corporate profile and contacts in Carlsbad, California.